Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC®
Bavarian Nordic and Bristol-Myers Squibb announced an agreement that provides Bristol-Myers Squibb an exclusive option to license and commercialize PROSTVAC®, Bavarian Nordic’s investigational Phase 3 prostate-specific antigen-targeting cancer immunotherapy. March 04, 2015